CD19 and neuroblastoma: They were tested in parallel with CD19.CAR-T cells (negative control, the CD19 antigen being a B lymphocyte marker not present on neuroblastoma cells) and, as a positive control, CAR-T cells against the validated and clinically targetable neuroblastoma antigen GD2.